Literature DB >> 15588037

The course of inhalation profiles during an exacerbation of obstructive lung disease.

Mariëlle E A C Broeders1, Johan Molema, Wim C J Hop, Niek A Vermue, Hans Th M Folgering.   

Abstract

BACKGROUND: Acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) are associated with increased airflow Limitation, hyperinflation and respiratory muscle fatigue. It is unclear, whether patients are able to perform adequate inhalations through various inhalation devices with different orfices during an exacerbation. The aim of this study was to examine the evolution of inhalation profiles of patients inhaling through Diskus, Turbuhaler, pressurized metered dose inhaler (pMDI) and Volumatic and consequently the appropriateness of using the various devices during an exacerbation. MEASUREMENTS: 15 hospitalized patients participated in this randomized comparison of inhalation profiles through the four placebo-devices. For each device, triplicate inhalation profiles were recorded during day 1-9 of admission and in stable phase (day 50).
RESULTS: The mean percentage of patients performing optimum inhalation profiles was 100% for Diskus, 60% for Turbuhaler, 14% for pMDI and 87% for Volumatic over the interval of day 1-9 and day 50. Patients with an inspiratory muscle strength (MIP) of less than 6kPa were generally unable to generate the optimum flow through the Turbuhaler (>60 l/min).
CONCLUSION: The Diskus and Volumatic can be used effectively in the acute phase of an exacerbation of asthma or COPD. The Turbuhaler could be optimally used after the fifth day of convalescence. The pMDI is rather unsuitable during an exacerbation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588037     DOI: 10.1016/j.rmed.2004.04.010

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  20 in total

Review 1.  Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.

Authors:  Sohini Ghosh; Jill A Ohar; M Bradley Drummond
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-09-21       Impact factor: 2.849

2.  Evaluation of the use of inhaled medications by hospital inpatients with chronic obstructive pulmonary disease.

Authors:  Joshua Batterink; Karen Dahri; Amneet Aulakh; Carmen Rempel
Journal:  Can J Hosp Pharm       Date:  2012-03

3.  High Prevalence of Suboptimal Peak Inspiratory Flow in Hospitalized Patients With COPD: A Real-world Study.

Authors:  Donald A Mahler; Shaban Demirel; Ramon Hollander; Gokul Gopalan; Asif Shaikh; Cathy D Mahle; Jessica Elder; Curtis Morrison
Journal:  Chronic Obstr Pulm Dis       Date:  2022-07-29

4.  Low Peak Inspiratory Flow Rates are Common Among COPD Inpatients and are Associated with Increased Healthcare Resource Utilization: A Retrospective Cohort Study.

Authors:  Brendan Clark; Brian J Wells; Amit K Saha; Jessica Franchino-Elder; Asif Shaikh; Bonnie M K Donato; Jill A Ohar
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-06-29

5.  Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.

Authors:  L Pekka Malmberg; Paula Rytilä; Pertti Happonen; Tari Haahtela
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

6.  Room air dilution of heliox given by facemask.

Authors:  Thomas D A Standley; Helen L Smith; Liam J Brennan; Ingrid A Wilkins; Peter G Bradley; Casiano Barrera Groba; Andrew J Davey; David K Menon; Daniel W Wheeler
Journal:  Intensive Care Med       Date:  2008-03-19       Impact factor: 17.440

7.  In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing.

Authors:  Renishkumar R Delvadia; Xiangyin Wei; P Worth Longest; Jurgen Venitz; Peter R Byron
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-10-08       Impact factor: 2.849

8.  Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate.

Authors:  Donald A Mahler; Jill A Ohar; Chris N Barnes; Edmund J Moran; Srikanth Pendyala; Glenn D Crater
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23

9.  Appropriate use of a dry powder inhaler based on inhalation flow pattern.

Authors:  Tetsuri Kondo; Makoto Hibino; Toshimori Tanigaki; Stanley M Cassan; Sakurako Tajiri; Kenichro Akazawa
Journal:  J Pharm Health Care Sci       Date:  2017-01-18

10.  Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting.

Authors:  Janine A M Westerik; Victoria Carter; Henry Chrystyn; Anne Burden; Samantha L Thompson; Dermot Ryan; Kevin Gruffydd-Jones; John Haughney; Nicolas Roche; Federico Lavorini; Alberto Papi; Antonio Infantino; Miguel Roman-Rodriguez; Sinthia Bosnic-Anticevich; Karin Lisspers; Björn Ställberg; Svein Høegh Henrichsen; Thys van der Molen; Catherine Hutton; David B Price
Journal:  J Asthma       Date:  2016-01-26       Impact factor: 2.515

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.